Select Neurotech & AI Portfolio
Where Visionary Science Meets Venture Excellence
Kaleida Capital’s portfolio represents the future's most promising neurotech and AI companies, carefully selected through our rigorous scientific diligence and strategic vision.
Each investment demonstrates our commitment to backing exceptional founders building breakthrough technologies in neural engineering and artificial intelligence.
-
(ACQUIRED 2024) A computational neuroimaging platform improving drug development for patients with schizophrenia and bipolar disorders.
-
A wireless power transfer platform enabling safe, efficient energy delivery for implantable medical devices and electrified systems.
-
Wearable neurostimulation device designed for rapid deployment in the ICU.
-
A clinical-stage endovascular brain-computer interface enabling minimally invasive neural access for communication and cognitive applications.
-
A high-bandwidth brain-computer interface restoring speech and motor function in patients with paralysis, ALS, and spinal cord injuries.
-
A neurotechnology platform building integrated neural interfaces and machine intelligence systems to restore and augment human vision and cognition.
-
The developer of Claude, focused on safety-aligned large language models and foundational systems for reliable and interpretable intelligence.
-
The developer of ChatGPT, a global AI platform and backer of BCI company, Merge Labs.
-
A therapeutic platform targeting protein misfolding to treat neurodegenerative disease at its molecular root.